1. Acute eosinophilic pneumonia after changing dosing schedule of nivolumab. (3rd August 2021) Authors: Shinada, Kanako; Murakami, Shuji; Sugimoto, Hideyasu; Saito, Haruhiro Journal: Japanese journal of clinical oncology Issue: Volume 51:Number 12(2021) Page Start: 1766 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010). Issue 12 (21st September 2022) Authors: Kenmotsu, Hirotsugu; Sugawara, Shunichi; Watanabe, Yasutaka; Saito, Haruhiro; Okada, Morihito; Chen‐Yoshikawa, Toyofumi Fengshi; Ohe, Yuichiro; Nishio, Wataru; Nakagawa, Shizuka; Nagao, Haruka Journal: Cancer science Issue: Volume 113:Issue 12(2022) Page Start: 4327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next‐generation sequencing technique. Issue 8 (23rd June 2020) Authors: Manabe, Saki; Kasajima, Rika; Murakami, Shuji; Miyagi, Yohei; Yokose, Tomoyuki; Kondo, Tetsuro; Saito, Haruhiro; Ito, Hiroyuki; Kaneko, Takeshi; Yamada, Kouzo Journal: Thoracic cancer Issue: Volume 11:Issue 8(2020) Page Start: 2262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti‐PD‐1 inhibitor. Issue 5 (12th November 2018) Authors: Matsuo, Norikazu; Azuma, Koichi; Hattori, Satoshi; Ohtake, Junya; Kawahara, Akihiko; Ishii, Hidenobu; Tokito, Takaaki; Yamada, Kazuhiko; Shibata, Yuji; Shimokawaji, Tadasuke; Kondo, Tetsuro; Kato, Terufumi; Saito, Haruhiro; Yamada, Kouzo; Sasada, Tetsuro; Hoshino, Tomoaki Journal: International journal of cancer Issue: Volume 144:Issue 5(2019) Page Start: 1170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial. Issue 7 (1st February 2016) Authors: Takeda, Masayuki; Yamanaka, Takeharu; Seto, Takashi; Hayashi, Hidetoshi; Azuma, Koichi; Okada, Morihito; Sugawara, Shunichi; Daga, Haruko; Hirashima, Tomonori; Yonesaka, Kimio; Urata, Yoshiko; Murakami, Haruyasu; Saito, Haruhiro; Kubo, Akihito; Sawa, Toshiyuki; Miyahara, Eiji; Nogami, Naoyuki; Na... Journal: Cancer Issue: Volume 122:Issue 7(2016) Page Start: 1050 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Issue 1 (January 2022) Authors: Kawashima, Yosuke; Fukuhara, Tatsuro; Saito, Haruhiro; Furuya, Naoki; Watanabe, Kana; Sugawara, Shunichi; Iwasawa, Shunichiro; Tsunezuka, Yoshio; Yamaguchi, Ou; Okada, Morihito; Yoshimori, Kozo; Nakachi, Ichiro; Seike, Masahiro; Azuma, Koichi; Kurimoto, Futoshi; Tsubata, Yukari; Fujita, Yuka; Nag... Journal: Lancet Issue: Volume 10:Issue 1(2022) Page Start: 72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study). (February 2020) Authors: Shimizu, Junichi; Masago, Katsuhiro; Saito, Haruhiro; Nishino, Kazumi; Kurata, Takayasu; Itoh, Yohji; Yoshimura, Yoko; Yabuki, Yutaka; Dosaka-Akita, Hirotoshi Journal: Therapeutic advances in medical oncology Issue: Volume 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Issue 10212 (23rd November 2019) Authors: Paz-Ares, Luis; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libor; Bondarenko, Igor; Kazarnowic... Journal: Lancet Issue: Volume 394:Issue 10212(2019) Page Start: 1929 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study. Issue 6 (20th February 2023) Authors: Johnson, Melissa L.; Cho, Byoung Chul; Luft, Alexander; Alatorre-Alexander, Jorge; Geater, Sarayut Lucien; Laktionov, Konstantin; Kim, Sang-We; Ursol, Grygorii; Hussein, Maen; Lim, Farah Louise; Yang, Cheng-Ta; Araujo, Luiz Henrique; Saito, Haruhiro; Reinmuth, Niels; Shi, Xiaojin; Poole, Lynne; P... Journal: Journal of clinical oncology Issue: Volume 41:Issue 6(2023) Page Start: 1213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Issue 1 (January 2021) Authors: Goldman, Jonathan W; Dvorkin, Mikhail; Chen, Yuanbin; Reinmuth, Niels; Hotta, Katsuyuki; Trukhin, Dmytro; Statsenko, Galina; Hochmair, Maximilian J; Özgüroğlu, Mustafa; Ji, Jun Ho; Garassino, Marina Chiara; Voitko, Oleksandr; Poltoratskiy, Artem; Ponce, Santiago; Verderame, Francesco; Havel, Libo... Journal: Lancet oncology Issue: Volume 22:Issue 1(2021) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗